Pdg82 Impact of Statin Adherence on Clinical Outcomes in Newly Treated Patients for Primary and Secondary Prevention: A Retrospective Study Based on Claims Database in China

Abstract

Both were licensed for oncology indications. These agents have received generally positive HTA appraisals: SMC have accepted both (Xofigo® conditional on a Patient Access Scheme [PAS]) and NICE recommended both (conditional on PAS; Xofigo® received an 'optimized' recommendation). G-BA deemed Xofigo® offered a 'considerable' additional benefit in one population and Lutathera® received automatic additional benefit as an orphan drug. Lutathera® attained ASMR III by HAS and the only identified negative HTA outcome was that by HAS of Xofigo® (ASMR IV). The ICER body had not evaluated either radiopharmaceutical. The mean time from EC-approval to positive HTA decision was 182.8 days. Conclusions: The limited number of therapeutic radiopharmaceuticals available have achieved broad and rapid reimbursement in major European markets. Their additional handling, manufacturing and storage costs have not outweighed the value of their patient benefits.